BioCentury | Nov 3, 2014
Company News

AKTivate Therapeutics, Virax deal

...up to 100 million additional shares valued at A$1 million ($879,400) tied to clinical milestones. Virax...
...Virax plans to start a Phase Ib trial of TCN-P for leukemia in early 2015. Virax...
...30% overall response rate (ORR) in ovarian cancer; and greater than 40% ORR in leukemia. Virax...
BioCentury | Aug 18, 2008
Clinical News

VIR201: Phase I/IIa start

...Next quarter, Virax will begin a double-blind, placebo-controlled, South African Phase I/IIa trial in about 140...
...begin a double-blind, placebo-controlled, South African Phase I/IIa trial in about 140 HIV-1 positive patients. Virax Holdings Ltd....
BioCentury | Dec 24, 2007
Company News

Virax management update

Virax Holdings Ltd. (ASX:VHL), Melbourne, Australia Business: Infectious, Cancer Promoted: Larry Ward to CEO from development director; he replaces David Beames, who resigned WIR Staff cancer Infectious...
BioCentury | Jun 11, 2007
Company News

Transgene, Virax deal

...immunotherapy technology to develop the vaccine (see BioCentury, March 19). Transgene S.A. (Euronext:Transgene), Strasbourg, France Virax Holdings Ltd....
BioCentury | Mar 19, 2007
Company News

Transgene, Virax deal

...million in license fees and milestones, plus North American royalties. Transgene S.A. (Euronext:Transgene), Strasbourg, France Virax Holdings Ltd....
BioCentury | Oct 23, 2006
Clinical News

VIR201: IND submitted

...VHL submitted an IND to FDA to begin a Phase II trial. Virax Holdings Ltd. (ASX:VHL), Melbourne, Australia...
BioCentury | Sep 11, 2006
Finance

Ebb & Flow

...PROVE 2 and to start PROVE 3. VX-950 is partnered with Johnson & Johnson (JNJ). Virax...
BioCentury | Oct 17, 2005
Strategy

Infectious vaccine players

...herpes $21.6 Immune Response (IMNR) HIV/AIDS $19.7 Tripep (SSE:TPEP) Hepatitis C, HIV/AIDS and others $14.8 Virax...
BioCentury | Feb 16, 2004
Clinical News

VIR201: Phase I/IIa

...HIV drugs. Data were presented at the Retroviruses and Opportunistic Infections conference in San Francisco. Virax Holdings Ltd....
BioCentury | Sep 9, 2002
Clinical News

VIR201: Phase I/IIa

...however, in the 20-week extension study patients will continue VIR201 and stop other HIV drugs. Virax Holdings Ltd....
Items per page:
1 - 10 of 20
BioCentury | Nov 3, 2014
Company News

AKTivate Therapeutics, Virax deal

...up to 100 million additional shares valued at A$1 million ($879,400) tied to clinical milestones. Virax...
...Virax plans to start a Phase Ib trial of TCN-P for leukemia in early 2015. Virax...
...30% overall response rate (ORR) in ovarian cancer; and greater than 40% ORR in leukemia. Virax...
BioCentury | Aug 18, 2008
Clinical News

VIR201: Phase I/IIa start

...Next quarter, Virax will begin a double-blind, placebo-controlled, South African Phase I/IIa trial in about 140...
...begin a double-blind, placebo-controlled, South African Phase I/IIa trial in about 140 HIV-1 positive patients. Virax Holdings Ltd....
BioCentury | Dec 24, 2007
Company News

Virax management update

Virax Holdings Ltd. (ASX:VHL), Melbourne, Australia Business: Infectious, Cancer Promoted: Larry Ward to CEO from development director; he replaces David Beames, who resigned WIR Staff cancer Infectious...
BioCentury | Jun 11, 2007
Company News

Transgene, Virax deal

...immunotherapy technology to develop the vaccine (see BioCentury, March 19). Transgene S.A. (Euronext:Transgene), Strasbourg, France Virax Holdings Ltd....
BioCentury | Mar 19, 2007
Company News

Transgene, Virax deal

...million in license fees and milestones, plus North American royalties. Transgene S.A. (Euronext:Transgene), Strasbourg, France Virax Holdings Ltd....
BioCentury | Oct 23, 2006
Clinical News

VIR201: IND submitted

...VHL submitted an IND to FDA to begin a Phase II trial. Virax Holdings Ltd. (ASX:VHL), Melbourne, Australia...
BioCentury | Sep 11, 2006
Finance

Ebb & Flow

...PROVE 2 and to start PROVE 3. VX-950 is partnered with Johnson & Johnson (JNJ). Virax...
BioCentury | Oct 17, 2005
Strategy

Infectious vaccine players

...herpes $21.6 Immune Response (IMNR) HIV/AIDS $19.7 Tripep (SSE:TPEP) Hepatitis C, HIV/AIDS and others $14.8 Virax...
BioCentury | Feb 16, 2004
Clinical News

VIR201: Phase I/IIa

...HIV drugs. Data were presented at the Retroviruses and Opportunistic Infections conference in San Francisco. Virax Holdings Ltd....
BioCentury | Sep 9, 2002
Clinical News

VIR201: Phase I/IIa

...however, in the 20-week extension study patients will continue VIR201 and stop other HIV drugs. Virax Holdings Ltd....
Items per page:
1 - 10 of 20